Company Performance Metrics
Colin Giles: Vice President Clinical & Regulatory AffairsPast Role: Zoetis, Vice President for Veterinary Medicine Pharmaceuticals R&D
David Gearing: Co-Founder & CSOPast Role: University of Queensland, Entrepreneur-in-Residence
Our mission is to be a revolutionary force in the growing US$25 billion global animal pharmaceutical market. Only Nexvet can produce therapeutic antibodies that are 100% customised to target new species – like cats and dogs.
Monoclonal antibody therapies have represented a new generation of highly effective, safe and targeted medicines in
humans. We think it’s time companion animals reaped the benefits of human medical progress in this field.
Nexvet’s unique technology, PETisation™, ensures 100% customisation of a therapy to a new species, reducing the chances of immune challenges, and ensuring a more ‘natural’ fit between the therapy and the patient. Many chronic conditions in pets remain poorly treated by current veterinary therapies, such as pain and various inflammatory diseases– which has guided Nexvet’s focus towards these indications.
To ensure we succeed in transforming animal medicine, we’ve brought together a team with an extraordinary global track record in animal and human health. We are working with leading contractors, advisors, drug development partners, academic groups, veterinarians and animal interest groups around the world to develop our pipeline to the highest standards.
Senior executives and researchers from the world’s largest animal health brands are counted among our Board, management, and advisors, and together we’re building connections worldwide to make our vision a reality.
